Literature DB >> 1592872

Pitfalls in diagnosing impaired growth hormone (GH) secretion: retesting after replacement therapy of 63 patients defined as GH deficient.

E Cacciari1, P Tassoni, G Parisi, P Pirazzoli, S Zucchini, M Mandini, A Cicognani, A Balsamo.   

Abstract

Possible causes of error in the diagnosis of isolated GH deficiency are the variability of GH response to repeated tests, the existence of transient GH deficiencies, and the low GH levels found in short statured children with delayed puberty. Sixty-three patients with variously expressed GH deficiency were retested (1 sleep test and 2 pharmacological tests) after 1-3.9 yr of GH therapy (dose, 15 U/m2.week). Forty-eight subjects had arginine, L-dopa, and sleep tests (mean serum GH concentration) twice, while 15 had only arginine and L-dopa tests. All patients were retested 1 month after withdrawal from therapy. The criteria used to subdivide the patients were pubertal development and response to pharmacological and sleep tests at first diagnosis and on retesting. The initial diagnosis in 33 subjects (52.4%) was not confirmed, and 13 (20.6%) were no longer deficient on retesting. The percentage of normalization was high for the sleep test (43.9%), lower for the pharmacological test (24.5%), and lower still (12.9%) for pharmacological and sleep tests considered together. While none of the 28 subjects who remained prepubertal at retesting normalized in any of the tests, 13 of the 35 subjects retested during puberty did. When normalization was observed in pubertal subjects, it occurred predominantly in the sleep test. Growth velocity and height age/bone age increment ratio after the first year of therapy were no different for the groups of subjects classified according to GH secretion on retesting. Our study demonstrates that a number of children diagnosed as GH deficient do not have a true deficiency. However, such a diagnostic error seems to have little effect, at least in the first year of therapy, on the effectiveness of GH treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1592872     DOI: 10.1210/jcem.74.6.1592872

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  14 in total

Review 1.  Growth hormone treatment in adults with growth hormone deficiency: the transition.

Authors:  M E Molitch
Journal:  J Endocrinol Invest       Date:  2011-01-26       Impact factor: 4.256

2.  Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA.

Authors:  G Aimaretti; R Attanasio; S Cannavò; M C Nicoletti; R Castello; C Di Somma; P Garofalo; L Iughetti; S Loche; M Maghnie; L Mazzanti; G Saggese; M Salerno; G Tonini; V Toscano; S Zucchini; M Cappa
Journal:  J Endocrinol Invest       Date:  2014-11-02       Impact factor: 4.256

3.  Sequential administration of arginine and arginine plus GHRH to test somatotroph function in short children.

Authors:  J Bellone; G Aimaretti; S Bellone; C Baffoni; G Corneli; C Origlia; M Cappa; E Ghigo
Journal:  J Endocrinol Invest       Date:  2000-02       Impact factor: 4.256

Review 4.  Growth hormone treatment in non-growth hormone-deficient short children.

Authors:  S Loche; M R Casini; G M Ubertini; M Cappa
Journal:  J Endocrinol Invest       Date:  2005-02       Impact factor: 4.256

5.  Final height of short subjects of low birth weight with and without growth hormone treatment.

Authors:  S Zucchini; E Cacciari; A Balsamo; A Cicognani; D Tassinari; E Barbieri; S Gualandi
Journal:  Arch Dis Child       Date:  2001-04       Impact factor: 3.791

6.  Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.

Authors:  G Guzzaloni; G Grugni; F Morabito
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

7.  Early retesting by GHRH + arginine test shows normal GH response in most children with idiopathic GH deficiency.

Authors:  C Bizzarri; S Pedicelli; B Boscherini; G Bedogni; M Cappa; S Cianfarani
Journal:  J Endocrinol Invest       Date:  2014-11-07       Impact factor: 4.256

8.  Urinary growth hormone estimation in diagnosing severe growth hormone deficiency.

Authors:  P Pirazzoli; M Mandini; S Zucchini; S Gualandi; L Vignutelli; M Capelli; E Cacciari
Journal:  Arch Dis Child       Date:  1996-09       Impact factor: 3.791

9.  Short procedure of GHRH plus arginine test in clinical practice.

Authors:  G Aimaretti; S Bellone; C Baffoni; G Cornel; C Origlia; L Di Vito; S Rovere; E Arvat; F Camanni; E Ghigo
Journal:  Pituitary       Date:  2001-08       Impact factor: 4.107

10.  Effect of body mass index on peak growth hormone response to provocative testing in children with short stature.

Authors:  Takara L Stanley; Lynne L Levitsky; Steven K Grinspoon; Madhusmita Misra
Journal:  J Clin Endocrinol Metab       Date:  2009-11-04       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.